By Catherine Lemay
Health Canada is considering revising the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") Guidance Document with respect to whether administrative drug submissions submitted by a generic manufacturer pursuant to a licensing agreement will trigger section 5 of the PM(NOC) Regulations requiring the party to address the patents listed on the Patent Register against the innovator drug.